AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32958482 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM testing
Number of subjects: 150
Study 32958482 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment IgM concentrations
Number of subjects: 150
Study 32958482 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM EIAs and IgM LIA
Number of subjects: 150
Study 32958482 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM detection
Number of subjects: 150
Study 32958484 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week behavioural intervention targeting physical activity delivered once per week by telephone
Number of subjects: 16
Study 32958484 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorsement of interventions by clinicians
Number of subjects: 16
Study 32958484 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual tailoring of the intervention
Number of subjects: 16
Study 32958484 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouraging family members to attend consultations
Number of subjects: 16
Study 32958484 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-support for long-term maintenance
Number of subjects: 16
Study 32958488 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised lumbar cerebrospinal fluid pressure (CSFP) monitoring before, during, and 24 hours after operation
Number of subjects: 20
Study 32958488 — intervention group
Group type: EXPERIMENTAL
Intervention: CSFP monitoring
Number of subjects: 20
Study 32958488 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial blood pressure recording perioperatively and postoperatively
Number of subjects: 20
Study 32958488 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of CSFP
Number of subjects: 20
Study 32958488 — intervention group
Group type: EXPERIMENTAL
Intervention: CSFP fluid dynamics and pressure analysis preoperative, perioperative and postoperative
Number of subjects: 20
Study 32958488 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative spinal perfusion analysis
Number of subjects: 20
Study 32958488 — intervention group
Group type: EXPERIMENTAL
Intervention: Waveform morphology analysis
Number of subjects: 20
Study 32958628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Closed-Loop Insulin Therapy
Number of subjects: 0
Study 32958709 — intervention group
Group type: EXPERIMENTAL
Intervention: 140-mg loading dose of caspofungin (CAS)
Number of subjects: 0
Study 32959043 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeSurfer-derived estimates of average convexity
Number of subjects: 1096
Study 32959043 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeSurfer-derived estimates of mean curvature
Number of subjects: 1096
Study 32959043 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial permutation analysis
Number of subjects: 1096
Study 32959043 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotypic correlations between average convexity, curvature, and surface metrics
Number of subjects: 1096
Study 32959085 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-arterial radioembolization (TARE) with Y90 resin microspheres
Number of subjects: 1027
Study 32959670 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching intervention (1:1 sessions over 8 weeks)
Number of subjects: 287
Study 32959786 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-Enhanced Prevention Support (MEPS) intervention group
Number of subjects: 300
Study 32959786 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 300
Study 32959922 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rivaroxaban
Number of subjects: 12
Study 32959922 — intervention group
Group type: EXPERIMENTAL
Intervention: H. perforatum extract (after 2 weeks treatment)
Number of subjects: 12
Study 32959922 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements before H. perforatum treatment)
Number of subjects: 12
Study 32959985 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox
Number of subjects: 1
Study 32960321 — intervention group
Group type: COMPARATOR
Intervention: Perimetric glaucoma patients
Number of subjects: 201
Study 32960321 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy control subjects
Number of subjects: 201
Study 32960659 — intervention group
Group type: EXPERIMENTAL
Intervention: β-lacta test
Number of subjects: 203
Study 32960728 — intervention group
Group type: EXPERIMENTAL
Intervention: MR elastography
Number of subjects: 0
Study 32960976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural intervention
Number of subjects: 269
Study 32961393 — intervention group
Group type: EXPERIMENTAL
Intervention: C9orf72 expansion
Number of subjects: 1
Study 32961547 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed (BF)
Number of subjects: 0
Study 32961547 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein-based formula (SF)
Number of subjects: 0
Study 32961547 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk-based formula (MF)
Number of subjects: 0
Study 32961802 — intervention group
Group type: EXPERIMENTAL
Intervention: SVF injection
Number of subjects: 20
Study 32962417 — intervention group
Group type: EXPERIMENTAL
Intervention: YKL-40 levels in patients with severe AS (n=572)
Number of subjects: 639
Study 32962417 — intervention group
Group type: EXPERIMENTAL
Intervention: YKL-40 levels in patients with mixed severity AS (n=67)
Number of subjects: 639
Study 32962417 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 639
Study 32962727 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure (PP)
Number of subjects: 26
Study 32962727 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal carbon dioxide (EtCO2)
Number of subjects: 26
Study 32962746 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) program, 4 weeks duration
Number of subjects: 58
Study 32963069 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 500
Study 32963279 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic brain-computer interface (Utrecht NeuroProsthesis) with electrode strips placed subdurally over the dorsolateral prefrontal cortex
Number of subjects: 2
Study 32963279 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting backwards to activate the dorsolateral prefrontal cortex
Number of subjects: 2
Study 32963347 — intervention group
Group type: EXPERIMENTAL
Intervention: buparlisib monotherapy
Number of subjects: 53
Study 32963347 — intervention group
Group type: EXPERIMENTAL
Intervention: buparlisib and cetuximab combination
Number of subjects: 53
Study 32963470 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate XR
Number of subjects: 115
Study 32963470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 32964020 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil fixed-dose combination
Number of subjects: 262
Study 32964203 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg/d)
Number of subjects: 80
Study 32964203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 32964317 — intervention group
Group type: EXPERIMENTAL
Intervention: Passeo-18 Lux drug-coated balloon (DCB)
Number of subjects: 151
Study 32964431 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation of human milk
Number of subjects: 204
Study 32964719 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) intervention with 13 required visits and an average of 26.3 hours spent at each site.
Number of subjects: 257
Study 32964719 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) intervention
Number of subjects: 257
Study 32965223 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-integrated PCD tool users
Number of subjects: 301
Study 32965227 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-based intervention via mobile app
Number of subjects: 80
Study 32965227 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 80
Study 32965234 — intervention group
Group type: EXPERIMENTAL
Intervention: Authenticated interactive websites
Number of subjects: 0
Study 32965234 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary team collaboration
Number of subjects: 0
Study 32965238 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention designed to promote physical activity (PA) and reduce sedentary time (ST)
Number of subjects: 2
Study 32965238 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 2
Study 32965238 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention
Number of subjects: 2
Study 32965540 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemarituzumab, dosage and schedule not specified
Number of subjects: 0
Study 32965540 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemarituzumab, projected dose and schedule to achieve target C
Number of subjects: 0
Study 32965548 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide (0.6 mg) alone
Number of subjects: 38
Study 32965548 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide (0.6 mg) with itraconazole (200 mg twice daily on day 1 and 200 mg once daily on days 2 through 9)
Number of subjects: 38
Study 32965548 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide (0.6 mg) with rifampin (600 mg QD days 1 through 13)
Number of subjects: 38
Study 32965659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor 150 mg orally every 12 hours for 104 weeks
Number of subjects: 121
Study 32965659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor (commercial)
Number of subjects: 121
Study 32966144 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV)
Number of subjects: 0
Study 32966176 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0
Study 32966176 — intervention group
Group type: COMPARATOR
Intervention: PCV10
Number of subjects: 0
Study 32966279 — intervention group
Group type: EXPERIMENTAL
Intervention: BMPR2 mutation carriers
Number of subjects: 73
Study 32966279 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients less than 30 years old
Number of subjects: 73
Study 32966279 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers
Number of subjects: 73
Study 32966308 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Blood Pressure Reduction (MB-BP)
Number of subjects: 26
Study 32966707 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic fluticasone propionate
Number of subjects: 0
Study 32967009 — intervention group
Group type: EXPERIMENTAL
Intervention: CART2 (second infusion of CD19 CAR T cells)
Number of subjects: 44
Study 32967451 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Hilar Clamping
Number of subjects: 0
Study 32967451 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32967637 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based clinical practice guideline (intervention)
Number of subjects: 213
Study 32967637 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-intervention)
Number of subjects: 213
Study 32967637 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for nurses (intervention)
Number of subjects: 213
Study 32967791 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAM2000 vaccination (Cohort 1)
Number of subjects: 14667
Study 32967791 — intervention group
Group type: COMPARATOR
Intervention: Non-vaccinated individuals (Cohort 2)
Number of subjects: 14667
Study 32967807 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab monotherapy (16 mg/kg, intravenously weekly for 8 weeks, biweekly for 16 weeks, and every 4 weeks thereafter)
Number of subjects: 49
Study 32967856 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 209867
Study 32967856 — intervention group
Group type: COMPARATOR
Intervention: DPP-4 inhibitors
Number of subjects: 209867
Study 32967864 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 35
Study 32967865 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention strategies for high-risk pregnancies identified at the end of the first trimester.
Number of subjects: 45000
Study 32967865 — intervention group
Group type: EXPERIMENTAL
Intervention: Creation of a new risk prediction model based on predictors recorded at the end of the first trimester.
Number of subjects: 45000
Study 32968030 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation and heavy alcohol use throughout adolescence
Number of subjects: 0
Study 32968030 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting factors and peer influences in early adolescence
Number of subjects: 0
Study 32968425 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 98
Study 32968425 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 98
Study 32968703 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized dietary recommendations
Number of subjects: 0
Study 32968703 — intervention group
Group type: EXPERIMENTAL
Intervention: Diverse macronutrient proportions
Number of subjects: 0
Study 32968710 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 1577
Study 32968710 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GLM)
Number of subjects: 1577
Study 32968710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Golimumab (GLM-IV)
Number of subjects: 1577
Study 32968892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence angiography with indocyanine green
Number of subjects: 32
Study 32968892 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperspectral imaging
Number of subjects: 32
Study 32968892 — intervention group
Group type: COMPARATOR
Intervention: Both methods (Fluorescence angiography and Hyperspectral imaging)
Number of subjects: 32
Study 32969154 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee flexion contracture (FC) severity categorized as none, mild, moderate, or severe.
Number of subjects: 8665
Study 32969154 — intervention group
Group type: COMPARATOR
Intervention: Knee flexion contracture (FC) severity in OA participants.
Number of subjects: 8665
Study 32969154 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee flexion contracture (FC) severity in relation to WOMAC outcomes.
Number of subjects: 8665
Study 32969154 — intervention group
Group type: COMPARATOR
Intervention: Knee flexion contracture (FC) severity and interaction with OA subcohort.
Number of subjects: 8665
Study 32969710 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32969724 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) 5 mg/kg/d
Number of subjects: 90
Study 32969724 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 32969832 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, visual probabilistic Opioid Risk Tool (ORT)
Number of subjects: 1302
Study 32969832 — intervention group
Group type: EXPERIMENTAL
Intervention: Video narrative-enhanced probabilistic Opioid Risk Tool (ORT)
Number of subjects: 1302
Study 32969832 — intervention group
Group type: COMPARATOR
Intervention: General risk information (Control)
Number of subjects: 1302
Study 32969834 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality meditation
Number of subjects: 30
Study 32969834 — intervention group
Group type: COMPARATOR
Intervention: Audio meditation
Number of subjects: 30
Study 32969834 — intervention group
Group type: COMPARATOR
Intervention: Virtual reality imagery
Number of subjects: 30
Study 32970845 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cerclage in combination with antibiotics (cefazolin or clindamycin) and a tocolytic (indomethacin)
Number of subjects: 73
Study 32970845 — intervention group
Group type: COMPARATOR
Intervention: Cervical cerclage alone
Number of subjects: 73
Study 32970962 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve stimulation
Number of subjects: 0
Study 32970962 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32971036 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus DHAP (dexamethasone, high-dose cytarabine, and cisplatin)
Number of subjects: 86
Study 32971231 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline gastric emptying tests (GES and WMC)
Number of subjects: 150
Study 32971231 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline gastric and small bowel contractile parameters (WMC)
Number of subjects: 150
Study 32971231 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables (female gender, stool form score, functional dyspepsia)
Number of subjects: 150
Study 32971231 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall upper GI symptoms and QOL scores
Number of subjects: 150
Study 32971266 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG microstate class C
Number of subjects: 0
Study 32971266 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG microstate classes A and B
Number of subjects: 0
Study 32971266 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigilance levels
Number of subjects: 0
Study 32972204 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose during CTO-PCI
Number of subjects: 0
Study 32972258 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32972320 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of PS (protein S) deficiency
Number of subjects: 89
Study 32972320 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of antiphospholipid antibodies (mainly lupus anticoagulant)
Number of subjects: 89
Study 32972320 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation abnormalities (activated partial thromboplastin time, D-dimer, fibrinogen, CRP)
Number of subjects: 89
Study 32972320 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombotic clinical events during hospitalization
Number of subjects: 89
Study 32972320 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquired thrombophilia
Number of subjects: 89
Study 32972570 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAO with the Amplatzer Amulet
Number of subjects: 1086
Study 32972574 — intervention group
Group type: EXPERIMENTAL
Intervention: Valvular Atrial Fibrillation (AF)
Number of subjects: 1472
Study 32972574 — intervention group
Group type: COMPARATOR
Intervention: Nonvalvular Atrial Fibrillation (AF)
Number of subjects: 1472
Study 32972574 — intervention group
Group type: COMPARATOR
Intervention: No Atrial Fibrillation (AF)
Number of subjects: 1472
Study 32972877 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy (PBT)
Number of subjects: 276880
Study 32972877 — intervention group
Group type: COMPARATOR
Intervention: External-Beam Radiation Therapy (EBRT)
Number of subjects: 276880
Study 32972877 — intervention group
Group type: COMPARATOR
Intervention: Brachytherapy (BT)
Number of subjects: 276880
Study 32973062 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest and thumb ECG monitoring two times per day for 28 days
Number of subjects: 100
Study 32973443 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Microphone Hearing Aids (RMHAs)
Number of subjects: 26
Study 32973475 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking time
Number of subjects: 0
Study 32973553 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming
Number of subjects: 52
Study 32973553 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study 32973614 — intervention group
Group type: EXPERIMENTAL
Intervention: Kibo therapeutic interview
Number of subjects: 60
Study 32973672 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 0
Study 32973672 — intervention group
Group type: COMPARATOR
Intervention: Motor Imagery-Assisted Brain-Computer Interface Training
Number of subjects: 0
Study 32973880 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 57
Study 32973880 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-OH-midazolam
Number of subjects: 57
Study 32973880 — intervention group
Group type: EXPERIMENTAL
Intervention: 4ß-OH-cholesterol
Number of subjects: 57
Study 32973880 — intervention group
Group type: EXPERIMENTAL
Intervention: 6ß-OH-cortisol
Number of subjects: 57
Study 32973912 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanins
Number of subjects: 160
Study 32973912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 32973950 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyponatremia
Number of subjects: 496
Study 32974034 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 28
Study 32974044 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Behavioural Activation (BA) - activity planning group
Number of subjects: 0
Study 32974044 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential Behavioural Activation (BA) - activity engagement group
Number of subjects: 0
Study 32974044 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 32974044 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional BA and Experiential BA
Number of subjects: 0
Study 32974088 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Learning (DL) regression models to predict best-corrected visual acuity (BCVA) from optical coherence tomography (OCT) images.
Number of subjects: 0
Study 32974088 — intervention group
Group type: EXPERIMENTAL
Intervention: DL binary classification models for predicting BCVA of Snellen equivalent of <20/40, <20/60, and ≤20/200.
Number of subjects: 0
Study 32974150 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical Intensity-Modulated Radiation Therapy
Number of subjects: 0
Study 32974208 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated intensity modulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) and pelvic lymph node coverage.
Number of subjects: 55
Study 32974255 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32974413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in nanophthalmic eyes
Number of subjects: 32
Study 32974413 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery in normal eyes
Number of subjects: 32